Biogen Inc. (BIIB) News
Filter BIIB News Items
BIIB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIIB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BIIB News From Around the Web
Below are the latest news stories about BIOGEN INC that investors may wish to consider to help them evaluate BIIB as an investment opportunity.
Biogen proposes to buy remaining stake in Sage in $442 million dealAs per the filing, Biogen has a 10.2% stake in Sage Therapeutics. Biogen has been navigating a slow pick-up in sales for its Alzheimer's drug Leqembi in the United States after concerns over cost, efficacy and side effects. Sage, whose shares fell 74.9% last year, abandoned the development of its drug dalzanemdor after multiple trial failures. |
Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing, higher-beta growth companies, the strategy underperformed its benchmark the Russell Mid Cap […] |
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assetsSasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire. |
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawAmbitious High-Speed Rail Plans Advance in the Baltic RegionA Blueprint for Better Bike LanesNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeCompanies including Biogen Inc. and Eli Lilly & Co. h |
Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory?Eli Lilly stock is trading below its key moving averages, but Zepbound just won a new approval. Is LLY stock now a buy? |
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ 100 stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, recently shared his perspective on the stock […] |
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the tech sector, so it's worth taking a look at the tech-heavy Nasdaq-100 index. In order from steepest decline to narrowest, the five unloved were Intel (NASDAQ: INTC), MongoDB (NASDAQ: MDB), Biogen (NASDAQ: BIIB), DexCom (NASDAQ: DXCM), and Microchip Technology (NASDAQ: MCHP). |
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challengesInvesting.com -- Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from “overweight” to “neutral,” given a challenging transition period for the biotech firm. The brokerage hacked the price target from $315 of $138, expressing concerns over Biogen's near-term revenue mix and the uphill battle in building its Alzheimer’s disease franchise. |
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
The 5 worst performing stocks on the Nasdaq 100 in 2024AI was huge in 2024. The underperformers list reflects challenges in the other sectors. |